Skip to main content
Top
Published in:

Open Access 01-12-2024 | Uveitis | Research

The effectiveness of the 0.19 mg fluocinolone acetonide implant in treating non-infectious posterior uveitis: a real-world experience

Authors: Igor Kozak, Avinash Gurbaxani, Maya Pandova

Published in: Journal of Ophthalmic Inflammation and Infection | Issue 1/2024

Login to get access

Abstract

Background

The 0.19 mg fluocinolone acetonide (FAc) implant (ILUVIEN) has been approved for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). There is little data assessing the long-term efficacy and safety of the FAc implant in this indication. Therefore, we conducted a retrospective interventional case review of 18 eyes from 13 patients with NIU-PS treated with the FAc implant at three ophthalmology departments in the Middle East between 2018 and 2021.

Main text

Baseline patient characteristics, including best-corrected visual acuity (BCVA), central retinal thickness (CRT) and intraocular pressure (IOP), were collected at the time of FAc implant administration and at 1–3 months, 6 months and every six months thereafter. The mean time of follow-up was 29.7 ± 14.6 (mean ± SD) months. Over the follow-up, the BCVA significantly increased from month 1 (P = 0.002) until month 36 (P = 0.024) and remained improving throughout the follow-up period (P = 0.004). The CRT significantly decreased from month 1 (P = 0.008) until month 12 (P = 0.003) and was persistently lower during the follow-up period (P = 0.022). Significant improvements in anterior chamber cells (P = 0.004) and vitritis scores (P = 0.001) were observed by Month 6. Similarly, at Month 12, significant improvements were noted in both parameters as well (anterior chamber cells: P = 0.012; vitritis scores: P = 0.004). Mean IOP remained relatively stable throughout (P = 0.205) the follow-up.

Conclusions

Our results suggest improvements and long-term maintenance in functional and anatomical outcomes with FAc implant with a manageable safety profile in a real-world clinical setting in patients with NIU-PS.
Literature
1.
go back to reference Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in northern California; the Northern California epidemiology of uveitis study. Ophthalmology 111:491–500CrossRefPubMed Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in northern California; the Northern California epidemiology of uveitis study. Ophthalmology 111:491–500CrossRefPubMed
2.
go back to reference Jabs DA, Nussenblatt RB, Rosenbaum JT et al (2005) Standardization of uveitis Nomenclature for reporting clinical data Results of the first International workshop. Am J Ophthalmol. 140:509–16CrossRefPubMed Jabs DA, Nussenblatt RB, Rosenbaum JT et al (2005) Standardization of uveitis Nomenclature for reporting clinical data Results of the first International workshop. Am J Ophthalmol. 140:509–16CrossRefPubMed
4.
go back to reference Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI (2004) Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88(9):1159–1162CrossRefPubMedPubMedCentral Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI (2004) Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88(9):1159–1162CrossRefPubMedPubMedCentral
5.
6.
go back to reference Nguyen QD, Hatef E, Kayen B, Macahilig CP, Ibrahim M, Wang J, Shaikh O, Bodaghi B (2011) A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology 118(1):184–190CrossRefPubMed Nguyen QD, Hatef E, Kayen B, Macahilig CP, Ibrahim M, Wang J, Shaikh O, Bodaghi B (2011) A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology 118(1):184–190CrossRefPubMed
7.
go back to reference Lightman S, Belfort R Jr, Naik RK, Lowder C, Foster CS, Rentz AM, Cui H, Whitcup SM, Kowalski JW, Revicki DA (2013) Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. Invest Ophthalmol Vis Sci 54(7):4864–4870CrossRefPubMed Lightman S, Belfort R Jr, Naik RK, Lowder C, Foster CS, Rentz AM, Cui H, Whitcup SM, Kowalski JW, Revicki DA (2013) Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. Invest Ophthalmol Vis Sci 54(7):4864–4870CrossRefPubMed
8.
go back to reference Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen jh, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE (2011) Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 118(10):1916–26CrossRef Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen jh, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE (2011) Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 118(10):1916–26CrossRef
9.
go back to reference Jaffe GJ, Lin P, Keenan RT, Ashton P, Skalak C, Stinnett SS (2016) Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results. Ophthalmology 123(9):1940–1948CrossRefPubMed Jaffe GJ, Lin P, Keenan RT, Ashton P, Skalak C, Stinnett SS (2016) Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results. Ophthalmology 123(9):1940–1948CrossRefPubMed
11.
go back to reference Jabs DA (2005) Standardization of uveitis nomenclature for reporting clinical data Results of the first international workshop. Am J Ophthalmol. 140:509–516CrossRefPubMed Jabs DA (2005) Standardization of uveitis nomenclature for reporting clinical data Results of the first international workshop. Am J Ophthalmol. 140:509–516CrossRefPubMed
13.
go back to reference Jaffe GJ, Foster CS, Pavesio CE, Paggiarino DA, Riedel GE (2019) Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology 126(4):601–610CrossRefPubMed Jaffe GJ, Foster CS, Pavesio CE, Paggiarino DA, Riedel GE (2019) Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology 126(4):601–610CrossRefPubMed
14.
go back to reference Jaffe GJ, Pavesio CE (2020) Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology 127(10):1395–1404CrossRefPubMed Jaffe GJ, Pavesio CE (2020) Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology 127(10):1395–1404CrossRefPubMed
15.
go back to reference Cai CX, Skalak C, Keenan RT, Grewal DS, Jaffe GJ (2020) Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant. Graefe’s Arch Clin Exp Ophthalmol 258(5):1023–1030CrossRef Cai CX, Skalak C, Keenan RT, Grewal DS, Jaffe GJ (2020) Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant. Graefe’s Arch Clin Exp Ophthalmol 258(5):1023–1030CrossRef
Metadata
Title
The effectiveness of the 0.19 mg fluocinolone acetonide implant in treating non-infectious posterior uveitis: a real-world experience
Authors
Igor Kozak
Avinash Gurbaxani
Maya Pandova
Publication date
01-12-2024
Publisher
Springer Berlin Heidelberg
Keyword
Uveitis
Published in
Journal of Ophthalmic Inflammation and Infection / Issue 1/2024
Electronic ISSN: 1869-5760
DOI
https://doi.org/10.1186/s12348-024-00409-x